The role and progress of CD47 in immune escape of hematological malignancies

QIN Liping,XIAO Ling,ZENG Ruolan,HE Yizi,LI Yajun,ZHOU Hui

DOI: https://doi.org/10.3969/j.issn.2095-1264.2023.05.04

2023-01-01

Abstract:Tumor immune escape plays a key role in the occurrence and development of hematological malignancies.At present,immunotherapy has become a research focus.CD47 is a highly glycosylated transmembrane protein widely ex-pressed on the surfaces of normal cells and tumor cells.Combined with the signal regulatory protein α(SIRPα),thrombos-pondin 1(TSP-1)and integrin,CD47 plays an important role in inflammation and tumor immune escape.CD47 on the sur-faces of tumor cells binds to the SIRPα on the surfaces of macrophages,inhibiting the phagocytosis of macrophages and pro-ducing tumor immune escape,thus promoting the occurrence and development of hematological malignancies.It has been proven in a variety of hematological malignancies that overexpression of CD47 is associated with poor prognosis.Many drugs targeting CD47 are undergoing preclinical and clinical studies in many types of hematological malignancies,and some of the drugs have shown good safety and promising efficacy.This paper summarizes the structure and function of CD47,the relation between CD47 and tumor-associated macrophage(TAM),the role of CD47 in immune escape of hemato-logical malignancies,and the research progress of CD47-targeted drugs.